Raymond James Keeps a Buy Rating on ICU Medical (ICUI)

By Austin Angelo

In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on ICU Medical (ICUIResearch Report), with a price target of $300. The company’s shares opened today at $247.65.

According to TipRanks.com, Bedford is a top 100 analyst with an average return of 19.3% and a 72.6% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Merit Medical Systems, and Edwards Lifesciences.

ICU Medical has an analyst consensus of Hold.

See today’s analyst top recommended stocks >>

Based on ICU Medical’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $219K. In comparison, last year the company had a net profit of $49.71 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ICU Medical, Inc. is an infusion therapy company, which engages in the development, manufacturing and sale of innovative medical devices used in vascular therapy and critical care applications. The company’s product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle-free connectors designed to help meet clinical, safety and workflow goals. Its customers are acute care hospitals, wholesalers, ambulatory clinics and alternate site facilities, such as clinics, home health care providers and long-term care facilities. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.